DAVID F EDWARDS
Plumbers in Boston, MA

6436443, Aug 20, 2002

Jun 25, 2001

09/888688

David A. Edwards - Boston MA
Giovanni Caponetti - Somerville MA
Jeffrey S. Hrkach - Cambridge MA
Noah Lotan - Haifa, IL
Justin Hanes - Baltimore MD
Robert S. Langer - Newton MA
Abdellaziz Ben-Jebria - State College PA

The Penn Research Foundation, Inc. - University Park PA
Massachesetts Institute of Technology - Cambridge MA

A61K 914

424489, 424 45, 424 46, 424490, 424491, 424502, 514 2, 514 3, 514826, 514851

Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a biodegradable material and have a mass density less than 0. 4 g/cm /. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear -hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, porous particles having a relatively large mean diameter, for example greater than 5 m, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The porous particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide variety of therapeutic agents.

2009020, Aug 20, 2009

Jan 9, 2009

12/351328

David A. Edwards - Boston MA, US
Howard A. Stone - Cambridge MA, US

A61K 9/14, C08B 37/00, C07K 14/00, A61K 31/74, A61K 38/16, A61K 31/715, C08B 37/02, C08G 65/34, C07K 14/76, A61K 31/721, A61K 31/765, A61K 38/38, A61P 31/12, A01K 29/00, A61D 7/00

424489, 5361231, 530350, 424 7808, 514 12, 514 54, 536112, 528425, 530362, 514 59, 424 7837, 119677

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles. These may include proteins such as albumin or polysaccharides such as dextran, which also has surface active properties, or polymers such as polyethylene oxide (PEO) or biodegradable synthetic polymers which can be used to encapsulate or deliver the materials to be delivered. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.

7556798, Jul 7, 2009

Jun 8, 2001

09/878146

David A. Edwards - Boston MA, US
Richard P. Batycky - Newton MA, US
Lloyd Johnston - Belmont MA, US

Alkermes, Inc. - Cambridge MA

A61K 9/12, A61K 9/14

424 45, 424 46, 424489, 424499, 514 2, 514 3, 12820315

A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0. 4 g/cmand deliver at least about 50% of the mass of particles. The particles are capable of carrying agents. The agent is (1) part of the spray-drying pre-mixture and thereby incorporated into the particles, (2) added to separately-prepared particles so that the agent is in chemical association with the particles or (3) blended so that the agent is mixed with, and co-delivered with the particles. Respirable compositions comprising carrier particles having a tap density of less than 0. 4 g/cmand a composition comprising an agent are also disclosed. Methods of delivering these respirable compositions are also included.

6977087, Dec 20, 2005

Mar 1, 2002

10/090418

David A. Edwards - Boston MA, US
Giovannia Caponetti - Piacenza, IT
Jeffrey S. Hrkach - Somerville MA, US
Noah Lotan - Haifa, IL
Justin Hanes - Baltimore MD, US
Abdell Aziz Ben-Jebria - State College PA, US
Robert S. Langer - Newton MA, US

Massachusetts Institute of Technology - Cambridge MA
The Penn State Research Foundation - University Park PA

A61K009/14, A61K009/16, A61K038/28

424489, 424499, 424501, 424502, 424 43, 424 45, 424 46, 424434, 514 3

Improved aerodynamically light particles for delivery to the pulmonary system, and methods for their preparation and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a tap density less than 0. 4 g/cmand a mass mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid group incorporated herein and at least on poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic or diagnostic agent to the alveolar region of the lung. The aerodynamically light particles optionally can incorporate a therapeutic or diagnostic agent, and may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of a wide variety of incorporated agents.

2005025, Nov 17, 2005

Apr 17, 2003

10/511413

David Edwards - Boston MA, US
Daniel Deaver - Franklin MA, US
Thaddeus Fulford-Jones - Cambridge MA, US
Jane Kucera - Acton MA, US

A61K038/22, A61K009/127, A61K009/14

424450000, 514012000, 424489000

A method and compositions for targeted drug delivery have been developed. The compositions include a targeting molecules such as a hormone that specifically binds to a receptor on the surface of the targeted cells; a drug to be delivered, such as a toxin that will kill the targeted cells; and a nanoparticle, which contains on or within the nanoparticle, the drug to be delivered, as well as has attached thereto, the targeting molecule. Nanoparticles can consist of drug or drug associated with carrier, such as a controlled or sustained release materials like a poly(lactide-co-glycolide), a liposome or surfactant. The compositions are administered by injections in most cases, although compositions can be applied topically orally, nasally, vaginally, rectally, and ocularly. Compositions can also be administered to the pulmonary or respiratory system, most preferably in an aerosol.

8591866, Nov 26, 2013

Apr 25, 2012

13/455585

David A. Edwards - Boston MA, US
Jonathan Chun-Wah Man - Cambridge MA, US
Jeffrey P. Katstra - Watertown MA, US
Robert W. Clarke - Medfield MA, US

Pulmatrix, Inc. - Lexington MA

A61K 9/00, A61K 9/12, A61K 9/14

424 46, 424489

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.

2011009, Apr 28, 2011

Oct 8, 2008

12/682353

David A. Edwards - Boston MA, US
Mathieu Lehanneur - Paris, FR

LE LABOGROUP S.A.S. - Paris

A61L 9/16, B01D 53/04, F24F 3/16

47 667, 47 655

A novel apparatus for the treatment, e.g., cleaning, humidifying, filtration and/or detoxifying, of ambient air incorporates a plant, soil, roots and a water reservoir to allow for effective filtration of air over an extended period of time. In particular, the device is designed with an air impeller system such that external ‘dirty’ air is circulated within the device in the proximity of the plant, soil, roots and/or water reservoir, thereby removing impurities, toxins and other undesirable chemicals from the air. The apparatus and methods of the present invention are readily applicable to a number of applications where air treatment is desired, e.g., household use. Moreover, by incorporating a plant system, the apparatus serves not only a functional but an aesthetic purpose as well.

2013004, Feb 21, 2013

Feb 22, 2011

13/580629

David A. Edwards - Boston MA, US
Raphaël Haumont - Longpont sur orge, FR
Francois Azambourg - Clichy, FR

A23P 1/08, A23L 2/00, A61K 9/00, A23L 1/00

424400, 426 89, 426103, 426392, 426393, 426303, 426135

Edible or potable substances can be transported in biodegradable vessel.